Alpha 2.0
Login Register
» Articles » PMID: 20724648

Initial Combination Therapy with Alogliptin and Pioglitazone in Drug-naïve Patients with Type 2 Diabetes

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 2010 Aug 21
PMID 20724648
Citations 40
Authors
Julio Rosenstock
Silvio E Inzucchi
Jochen Seufert
Penny R Fleck
Craig A Wilson
Qais Mekki
Affiliations
Soon will be listed here.
Abstract

Objective: To assess the efficacy and tolerability of alogliptin plus pioglitazone for initial combination therapy in drug-naïve type 2 diabetic patients.

Research Design And Methods: This 26-week, double-blind, parallel-group study randomized 655 patients with inadequately controlled type 2 diabetes to four arms: 25 mg alogliptin (A25) q.d. monotherapy, 30 mg pioglitazone (P30) q.d. monotherapy, or 12.5 (A12.5) or 25 mg alogliptin q.d. plus pioglitazone (P30) q.d. combination therapy. Primary efficacy was A1C change from baseline with the high-dose combination (A25+P30) versus each monotherapy.

Results: Combination therapy with A25+P30 resulted in greater reductions in A1C (-1.7±0.1% from an 8.8% mean baseline) vs. A25 (-1.0±0.1%, P<0.001) or P30 (-1.2±0.1%, P<0.001) and in fasting plasma glucose (-2.8±0.2 mmol/l) vs. A25 (-1.4±0.2 mmol/l, P<0.001) or P30 (-2.1±0.2 mmol/l, P=0.006). The A25+P30 safety profile was consistent with those of its component monotherapies.

Conclusions: Alogliptin plus pioglitazone combination treatment appears to be an efficacious initial therapeutic option for type 2 diabetes.

Citing Articles

Explainable Prediction of Long-Term Glycated Hemoglobin Response Change in Finnish Patients with Type 2 Diabetes Following Drug Initiation Using Evidence-Based Machine Learning Approaches.

Chandra G, Lavikainen P, Siirtola P, Tamminen S, Ihalapathirana A, Laatikainen T Clin Epidemiol. 2025; 17:225-240.

PMID: 40078337 PMC: 11899941. DOI: 10.2147/CLEP.S505966.

Benefits and risks of drug combination therapy for diabetes mellitus and its complications: a comprehensive review.

Xie X, Wu C, Hao Y, Wang T, Yang Y, Cai P Front Endocrinol (Lausanne). 2024; 14:1301093.

PMID: 38179301 PMC: 10766371. DOI: 10.3389/fendo.2023.1301093.

Initial Combination Therapy in Type 2 Diabetes.

Kim J, Kim N Endocrinol Metab (Seoul). 2023; 39(1):23-32.

PMID: 38031401 PMC: 10901659. DOI: 10.3803/EnM.2023.1816.

Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials.

He L, Wang J, Ping F, Yang N, Huang J, Li W BMJ. 2022; 377:e068882.

PMID: 35764326 PMC: 9237836. DOI: 10.1136/bmj-2021-068882.

Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study.

Kim H, Jeong I, Hur K, Kim S, Noh J, Chun S Diabetes Metab J. 2022; 46(5):689-700.

PMID: 35295073 PMC: 9532178. DOI: 10.4093/dmj.2021.0183.

References
1.
Rosenstock J, Kim S, Baron M, Camisasca R, Cressier F, Couturier A . Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007; 9(2):175-85. DOI: 10.1111/j.1463-1326.2006.00698.x. View
2.
McGuire D, Inzucchi S . New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications. Circulation. 2008; 117(3):440-9. DOI: 10.1161/CIRCULATIONAHA.107.704080. View
3.
Blonde L, Joyal S, Henry D, Howlett H . Durable efficacy of metformin/glibenclamide combination tablets (Glucovance) during 52 weeks of open-label treatment in type 2 diabetic patients with hyperglycaemia despite previous sulphonylurea monotherapy. Int J Clin Pract. 2004; 58(9):820-6. DOI: 10.1111/j.1742-1241.2004.00316.x. View
4.
Reynolds J, Neumiller J, Campbell R . Janumet: a combination product suitable for use in patients with Type 2 diabetes. Expert Opin Investig Drugs. 2008; 17(10):1559-65. DOI: 10.1517/13543784.17.10.1559. View
5.
Rosenstock J, Zinman B . Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2007; 14(2):98-107. DOI: 10.1097/MED.0b013e3280a02f65. View